Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Finished Goods: 2017-2024

Historic Finished Goods for China Pharma Holdings (CPHI) over the last 7 years, with Sep 2024 value amounting to $1.3 million.

  • China Pharma Holdings' Finished Goods rose 6.83% to $1.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.3 million, marking a year-over-year increase of 6.83%. This contributed to the annual value of $1.5 million for FY2023, which is 166.73% up from last year.
  • Latest data reveals that China Pharma Holdings reported Finished Goods of $1.3 million as of Q3 2024, which was down 15.80% from $1.5 million recorded in Q2 2024.
  • China Pharma Holdings' Finished Goods' 5-year high stood at $1.7 million during Q1 2024, with a 5-year trough of $551,000 in Q4 2021.
  • Moreover, its 3-year median value for Finished Goods was $1.3 million (2022), whereas its average is $1.3 million.
  • As far as peak fluctuations go, China Pharma Holdings' Finished Goods tumbled by 46.00% in 2021, and later surged by 166.73% in 2023.
  • Over the past 5 years, China Pharma Holdings' Finished Goods (Quarterly) stood at $960,375 in 2020, then slumped by 42.63% to $551,000 in 2021, then remained steady at $551,000 in 2022, then surged by 166.73% to $1.5 million in 2023, then climbed by 6.83% to $1.3 million in 2024.
  • Its last three reported values are $1.3 million in Q3 2024, $1.5 million for Q2 2024, and $1.7 million during Q1 2024.